Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferric carboxymaltose for pediatric iron deficiency anemia with inadequate response to oral iron
2019-003821-70Phase 3Completed
- Sponsor
- American Regent, Inc.
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of ferric carboxymaltose in iron deficiency anemia (IDA), sponsored by American Regent, Inc. Primary endpoint: Change in hemoglobin from baseline to Day 35. Started Nov 2019; status: completed.
02
Drugs
ferric carboxymaltose
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on 2019-003821-70.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003821-70.